Article Text

Download PDFPDF
Population-based incidence of intraocular tumours in Olmsted County, Minnesota
  1. Kafayat A Oyemade1,
  2. Timothy T Xu2,
  3. Johanny Lopez Dominguez3,
  4. Mihai G Dumbrava1,
  5. David O Hodge4,
  6. Launia J White4,
  7. Lauren A Dalvin2
  1. 1Mayo Clinic, Alix School of Medicine, Rochester, Minnesota, USA
  2. 2Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA
  3. 3Mayo Clinic, Alix School of Medicine, Jacksonville, Florida, USA
  4. 4Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA
  1. Correspondence to Dr Lauren A Dalvin, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA; dalvin.lauren{at}


Background/aims To determine population-based incidence of intraocular tumours in Olmsted County, Minnesota.

Methods Record review of the Rochester Epidemiology Project medical record linkage system from 1 January 2006 to 31 December 2015 for patient demographics, tumour type by clinical diagnosis and presence or absence of confirmation by histopathology. The incidence rate of any intraocular tumour and of each tumour type was calculated per million person-years. Poisson regression analysis was used to analyse changes in incidence over time.

Results There were 948 patients diagnosed with intraocular tumours resulting in an age-adjusted and sex-adjusted incidence rate of 727.5 per million (95% CI: 680.8 to 774.2, p<0.05). Most tumours were benign (953, 98%). Of the benign lesions, melanocytic lesions were the majority (942, 97%), with adjusted incidence rates of 646.9 (95% CI: 602.8 to 691.1) for choroidal nevus and 55.8 (95% CI: 43.2 to 64.8) for iris nevus. Malignant lesions were rare (16, 2%) with 13 cases of choroidal melanoma and 1 case each of iris melanoma, retinal leukaemic infiltration and metastasis. The adjusted incidence rate for choroidal melanoma was 7.1 (95% CI: 2.5 to 11.8).

Conclusion In a population-based setting, most intraocular tumours are benign and melanocytic. Although malignant lesions are less common, it is important to remain vigilant with appropriate monitoring given the potential for vision loss and life-threatening malignancy.

  • Epidemiology

Data availability statement

All data relevant to the study are included in the article or uploaded as supplemental information.

Statistics from

Data availability statement

All data relevant to the study are included in the article or uploaded as supplemental information.

View Full Text


  • Twitter @LADalvinMD

  • Correction notice This paper has been updated since it was first published. A funding statement has been added in the end statements.

  • Contributors LAD: conception of the study with supervision and critical revision of the manuscript. KAO, TTX, JLD and MGD: data collection. KAO, DH and LJW: data analysis. KAO: drafting of the manuscript.

  • Funding This study used the resources of the Rochester Epidemiology Project (REP) medical records-linkage system, which is supported by the National Institute on Aging (NIA; AG 058738), by the Mayo Clinic Research Committee, and by fees paid annually by REP users. The content of this article is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health (NIH) or the Mayo Clinic.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.